Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

232 Views

Poster Session: HAI: C.difficile

379 - **A budget impact analysis of bezlotoxumab for the management of recurrent Clostridioides difficile infection in the United States**

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

The ePoster content is available to users who are logged in.<br><br>Please click the login button at the top right corner and then come back here to use this button.

Co-Author(s)

YJ

Yiling Jiang, MSc

MSD (UK) Ltd.
London, England, United Kingdom
Abhishek Deshpande, MD, PhD

Staff
Cleveland Clinic
Cleveland, Ohio, United States

Presenting Author(s)

QL

Qinghua Li, PhD (she/her/hers)

Associate Director
Merck & Co., Inc.,
Rahway, New Jersey, United States

Co-Author(s)

LS

Lisa Siegartel, MPH

Merck & Co., Inc.
Rahway, New Jersey, United States
FS

Fakhar Siddiqui, MD, MBA

Merck & Co., Inc.
Rahway, New Jersey, United States
Engels N. Obi, PhD

Director Outcomes Research
Merck & Co., Inc
BASKING RIDGE, New Jersey, United States